Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We should hit the .14 to .18 range before earnings are released. You will see a lot of new posters arriving on this board.. Momentum is your friend.. USRM
Look forward to reading it.
Big jump in price and volume has attracted the eyes of interested investors. You will see a lot of new posters arriving on this board.. Double digits...USRM
This could double to .14 this week.
New Research: Key Drivers of Growth for Bioheart and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production
Growth Market Report Initiates Coverage on:
USRM DOWNLOAD: http://GrowthMarketReport.com/signup/?co=USRM
ELTP DOWNLOAD: http://GrowthMarketReport.com/signup/?co=ELTP
Bioheart Inc. (USRM) REPORT OVERVIEW
On March 6th, 2018, Bioheart Inc. closed out the trading session at $0.05 (up 0.21%), compared to the previous day close of $0.05. The volume on the day was 1,440,937 (up 36.35%), compared to the company's previous day volume of 1,056,790. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Bioheart reported revenue of $3.08MM vs $2.19MM (up 40.71%) and basic earnings per share -$0.09 vs -$1.80. Bioheart is expected to report earnings on March 21st, 2018, the report will be for the fiscal period ending December 31st, 2017.
Access Growth Market Report's Bioheart Inc. Research Report at:
http://GrowthMarketReport.com/signup/?co=USRM
Elite Pharmaceuticals Inc. (ELTP) REPORT OVERVIEW
On March 6th, 2018, Elite Pharmaceuticals Inc. closed out the trading session at $0.11 (up 2.90%), compared to the previous day close of $0.10. The volume on the day was 544,971 (up 6.31%), compared to the company's previous day volume of 512,608. For the twelve months ended March 31st, 2017 vs March 31st, 2016, Elite Pharmaceuticals reported revenue of $9.64MM vs $12.50MM (down 22.89%) and basic earnings per share $0.03 vs -$0.01. Elite Pharmaceuticals is expected to report earnings on June 13th, 2018, the report will be for the fiscal period ending March 31st, 2018.
Access Growth Market Report's Elite Pharmaceuticals Inc. Research Report at:
http://GrowthMarketReport.com/signup/?co=ELTP
Our Actionable Research on Bioheart Inc. (OTCQB: USRM) and Elite Pharmaceuticals Inc. (OTCQB: ELTP) can be downloaded free of charge at http://GrowthMarketReport.com/.
ABOUT Growth Market Report
It's no secret that Wall Street analysts spend the lion's share of their time focused on large, well-known companies and securities—they make most of their money from investment banking. As a result, small cap companies are relatively underserved when it comes to top-quality research and analysis. Growth Market Report was developed to fill in that gap.
DISCLAIMER
Growth Market Report is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at http://GrowthMarketReport.com/.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by Growth Market Report. Growth Market Report is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
Growth Market Report, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. Growth Market Report, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, Growth Market Report, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
https://finance.yahoo.com/news/research-key-drivers-growth-bioheart-123000728.html?.tsrc=rss
Earnings release Wednesday, March, 21st 2018
https://www.marketbeat.com/stocks/OTCMKTS/USRM/
US Stem Cell is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018.
Earnings release Wednesday, March, 21st 2018
https://www.marketbeat.com/stocks/OTCMKTS/USRM/
US Stem Cell is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018.
(CNN)Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the development of stem cell therapies proved to be safe and effective.
Dr. Scott Gottlieb, the FDA commissioner, and Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, co-authored a new paper detailing the delicate balance between safety and innovation when it comes to the possibilities of using stem cells in medicine.
"Our aim is to refashion our traditional tools for regulation to meet the challenges and opportunities presented by such highly innovative products as cell-based regenerative medicine," they wrote in the paper, published Thursday in the New England Journal of Medicine. Divisions run deep over how to regulate stem cell clinics.
Stem cells have the potential to develop into many cell types in the body. Some studies suggest that stem cells may help the nearly blind to see and could reverse signs of aging. Research has even explored using stem cells to create red blood cells to replenish blood shortages during emergencies.
"However, despite the increasingly widespread use of stem cells in techniques being labeled as regenerative medicine, clinical benefit has not been clearly shown in most instances," Gottlieb and Marks wrote.
The FDA hopes to change that, while continuing efforts to regulate the industry.
'A sweet spot of stem cell oversight'
"This more reflects an update from the FDA on where their thinking stands on stem cells. I don't see it as backing down from the hoped-for stepping up of FDA oversight of clinics," said Paul Knoepfler, professor of cell biology and human anatomy at the University of California, Davis School of Medicine, who wrote a blog post about the new paper.
"The FDA seems to be saying they want to find a sweet spot of stem cell oversight where they encourage innovation by good citizens and yet also carefully regulate this sphere as well as encouraging those interested in transplanting stem cells into patients to work with the FDA," he said.
Stem cell study offers hope for ALS
Knoepfler co-authored a paper, published in the journal Cell Stem Cell in 2016, that found unapproved stem cell interventions being marketed at 570 clinics across the US. "Hot spot" cities where there were clusters of clinics included Beverly Hills, California; New York; San Antonio; Los Angeles; Austin, Texas; Scottsdale, Arizona, and Phoenix.
Although Gottlieb and Marks didn't mention clinics in their paper, they noted that facilitating the availability of safe and effective therapies was part of the FDA's oversight of regenerative medicine products, including new stem cell therapies.
The FDA will provide tools to encourage individual or small groups of physicians to collaborate in support of the development of a stem cell or other regenerative medicine product, they wrote.
A milestone in stem cell research
A milestone in stem cell research
Gottlieb and Marks also said the FDA is encouraging investigators who are involved in such innovative product development to engage in dialogue with the agency early on in the research process.
"It feels like the FDA leadership is in essence telling them, 'Do the right thing, and we'll help you with a trial, even if you aren't a big university or company,' " Knoepfler said. "It's reassuring to see though that the FDA still emphasizes it is crucial to have data and follow the rules."
The FDA held a Grand Rounds webcast on Thursday detailing how its scientists are examining strategies and methods to predict the reliability of how certain cell-based therapies will perform in humans.
The ability to make such predictions could be a big step toward getting safe and effective FDA-approved treatments to patients in the future.
Predicting the future
For many investigational stem cell-based products, it remains unclear whether the measurements currently used to characterize products will predict their clinical effectiveness, according to the FDA.
As of now, stem cell-based products submitted to the FDA in clinical trial proposals are characterized using a small number of cell surface markers and simple measures of cell product activity -- but is that enough to truly predict clinical outcomes?
Stem Cells Fast Facts
Answering that question has become one of many focuses of the FDA's Multipotent Stromal Cell Consortium, a large team of scientists studying adult multipotent stromal cells. These are stem cells that can differentiate into a variety of cell types and could contribute to tissue repair or help replace, restore or regenerate other parts of the body.
Steven Bauer, chief of the cellular and tissues therapy branch in the Center for Biologics Evaluation and Research, gave the keynote presentation at Thursday's Grand Rounds and focused on how, when multipotent stromal cells are studied for use as therapies, predictability is key.
"We can use some of this information to help generate standards in this field," he said. "There is a tremendous amount of interest now in developing standards that will facilitate the development of regenerative medicine and products."
Follow CNN Health on Facebook and Twitter
See the latest news and share your comments with CNN Health on Facebook and Twitter.
All in all, "combined with the publication today of New England Journal of Medicine article, the FDA wants to assure that developers of regenerative medicine therapies understand the regulatory pathways that are available," the agency said in a written statement emailed to CNN by a FDA spokesperson.
"The FDA is committed to ensuring that patients have access to safe and effective regenerative medicine products as efficiently as possible. We are also committed to making sure we take action against products being unlawfully marketed that pose a potential significant risk to their safety," the statement said.
"The agency has adopted a risk-based and science-based approach that builds upon existing regulations to support innovative product development while clarifying the FDA's authorities and enforcement priorities. This risk-based approach allows product developers time to engage with the FDA, to determine if they need to submit a marketing authorization application and, if so, submit their application to the FDA for approval," the statement said.
US Stem Cell Inc (OTCMKTS:USRM) Momentum Favorite Back on the Move
By Jermaine Farmer - March 9, 2018
US Stem Cell Inc (OTCMKTS:USRM) has been back in rally mode in recent action. This was a major momentum play from early last year – one of the most dramatic stories on the OTC from Jan to March of 2017, rising from deep sub-penny levels to nearly $0.20/share in that time. It was a truly extraordinary run. The catalyst then had to do with a lawsuit that was worked out in a benign fashion. However, this time around, the stock is up a quick 50% in a few days, and breaking out to new multi-month highs, and the move appears to be driven by some more basic ideas related to its core stem cell strategy.
To augment that narrative, the company just announced its participation in this year’s fourth annual Academy of Regenerative Practices’ Conference, which kicked off last week and ran through March 2 & 3 at the Bonaventure Resort & Spa in Weston, Florida. That conference has come and gone at this point, so the stock’s continued advance raises our eyebrows. We always get interested when a company has made a key presentation and then starts to run on no new headlines. It has the scent of possible “smart money” flows based on key ideas presented at the event. But first, before we get into that thesis, here is a quick overview of the company for those who aren’t familiar with the name.
US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
The company’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
According to company materials, “USRM is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society
As noted above, shares of USRM have been back on the move following the company’s appearance at the Academy of Regenerative Practices’ Conference earlier this month.
“It’s always such a pleasure to gather with this rapidly expanding community of scientific experts to connect and collaborate,” said Dr. Kristin Comella, USRM’s Chief Science Officer and President of the Academy of Regenerative Practices. “This is an incredible time for regenerative medicine, and connecting with my colleagues in the scientific community who are passionate about it is always such a treat. I look forward to another successful conference with my colleagues from around the world.”
The chart shows 40% piled on for shareholders of the company during the trailing month. This is emblematic of the stock. USRM is a stock with a past that has featured a litany of sudden rips to the upside. In addition, the company has registered increased average transaction volume recently, with the past month seeing 49% over the long run average.
Currently trading at a market capitalization of $18.7, USRM has a bankroll ($957K) of cash on the books, which must be weighed relative to about $3.2M in total current liabilities. USRM is pulling in trailing 12-month revenues of $5M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 106.4%. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $USRM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $USRM, either long or short, and we have not been compensated for this article.
Earnings release Wednesday, March, 21st 2018
https://www.marketbeat.com/stocks/OTCMKTS/USRM/
US Stem Cell is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018.
Performance Report for Fri, Mar 9th, 2018
https://www.barchart.com/stocks/quotes/USRM/performance
Big jump in price and volume has attracted the eyes of interested investors. You will see a lot of new posters arriving on this board.. Double digits...USRM
U.S. Stem Cell Responds to FDA’s Regenerative Medicine Guidelines
November 21, 2017
https://www.businesswire.com/news/home/20171121006107/en/U.S.-Stem-Cell-Responds-FDA%E2%80%99s-Regenerative-Medicine
SUNRISE, Fla.--(BUSINESS WIRE)--U.S. Stem Cell, Inc. (OTC: USRM), a leader in development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to the recently-announced Food and Drug Administration’s comprehensive policy framework for the development and oversight of regenerative medicine products, including stem cell treatments.
@USStemCellInc Responds to FDA’s Regenerative Medicine Guidelines
Tweet this
The framework is described among four FDA guidance documents that build upon its existing, risk-based regulatory approach, that further describes regulation of drugs, devices, and/or biological products. It also includes regulatory guidance for off-the-shelf products that, due to their construct, require complex, lengthy and expensive entries to market, since they can involve using modified, third-party stem cells, which can require intense FDA scrutiny. According to USRM, its in-clinic stem cell procedures should not be subject to the same regulatory process as off-the-shelf drug products.
Due to high ramp-up costs with off-the-shelf gene or cell therapy products, patients can face prices of $475,000 per treatment. USRM’s proprietary, in-clinic protocols, using the patient’s own tissues/cells, are not off-the-shelf gene or cell therapies. Treatments are safely performed in-clinic, instead of a hospital, by physicians who are USRM-trained and certified in autologous stem cell therapy practices — procedures that are well documented in scientific literature, with few reported complications, and costs $5,000-$12,000.
“As U.S. Stem Cell continues to offer products, education and in-clinic therapeutic services, we remain in communication with the FDA to determine how we best fit into the stem cell therapies regulatory model,” said U.S. Stem Cell, Inc. President & CEO Mike Tomas. “We are hopeful the FDA will work with us to define fair regulation for the public.”
According to the FDA, these guidelines are intended to balance the agency’s commitment to safety, with mechanisms to drive advances in regenerative medicine, for innovators to bring patients new, effective therapies, quickly and safely.
“This is no longer the stuff of science fiction. This is the practical promise of modern applications of regenerative medicine,” said FDA Commissioner Scott Gottlieb, MD, in the guidelines.
“With the emerging field of stem cell therapy being dynamic and complex, the FDA is taking great consideration to ensure a comprehensive framework that simultaneously increases access to these innovations and ensures public safety,” added USRM Chief Science Officer Dr. Kristin Comella. “As we expand our business and pioneer this holistic approach, we are confident our position in emerging science will be reflected in the FDA’s regulatory decisions.”
USRM and its clinical affiliates have demonstrated a strong safety profile with in-clinic physician medical procedures, which are aligned with the risk-based approach the FDA intends to enforce. Supporting the belief that patients have a right to utilize their body’s cells to promote natural healing, USRM demonstrates the safety of these therapies in a recent publication within a peer-reviewed journal. The study describes the use of stromal vascular fraction (SVF) in the clinic for degenerative diseases in orthopedics, neurological and systemic conditions in 676 patients.
Additionally, USRM has spent more than $100 million over two decades on preclinical (animal) and clinical (human) trials using its MyoCell™ product; the published trials show culture-expanded autologous stem cells, directly injected into the heart, can provide benefit to congestive heart failure patients. USRM is actively seeking strategic partners to pursue commercialization of MyoCell™ and finalize Regenerative Medicine Advance Therapy (RMAT) designation, based on the draft guidelines published.
About U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.
Contacts
ANDER & Co
Suzanne Perez-Bernal, 786-888-4577
suzanne@anderpr.com
The FDA closes a huge loophole used by bogus stem-cell clinics, but delays serious enforcement for 3 years
http://www.latimes.com/business/hiltzik/la-fi-hiltzik-fda-stem-cell-20171117-story.html
By MICHAEL HILTZIK
NOV 17, 2017
The FDA closes a huge loophole used by bogus stem-cell clinics, but delays serious enforcement for 3 years
FDA Commissioner Scott Gottlieb, seen here testifying at his congressional confirmation hearing, is overseeing a crackdown on suspect stem cell clinics--but enforcement is years away. (J. Scott Applewhite / Associated Press)
There was good news and bad news in the regulatory initiative the Food and Drug Administration rolled out on Thursday, aimed partially at clinics marketing unproven stem-cell therapies directly to consumers.
The good news is that the FDA firmly closed a loophole exploited by many of these proliferating clinics. Those that say they're using liposuctioned fat to produce stem cells that they reinject in a patient to treat a host of medical conditions, the FDA says, are selling a drug. That means they need to be specially licensed and subjected to inspection.
BIOETHICIST LEIGH TURNER
Share quote & link
"Three years is a long time for potentially non-compliant clinics to still be raking in the dough from patients," observes Paul Knoepfler, a UC Davis stem-cell biologist who has spent more than a year documenting the spread of clinics hawking unproven stem-cell nostrums. The agency said it would prioritize enforcement during that period, focusing on "products that pose a potential significant safety concern."
Indeed, the FDA's hands-off approach to enforcing its own rules could encourage the further spread of such clinics, rather than clamping down on the proliferation. That's the view of Leigh Turner, a University of Minnesota bioethicist who co-wrote a survey of proliferating clinics with Knoepfler.
"This is nowhere close to a red line; at best, it's amber," Turner said of the FDA's enforcement plans. "A lot of people running these businesses are going to see this as an opportunity to carry on as before, or if they're not in the business, to dive into the marketplace." Over the next 36 months, he says, the direct-to-consumer stem-cell business is going to get larger, richer and more politically influential — and therefore more of a threat to public health.
The FDA on Thursday released four policy papers on stem-cell treatments. Two, aimed at regulating what we might think of as legitimate stem cell-based treatments, are draft guidelines open to public comment. The other two are final regulations aimed at the proliferating direct-to-consumer clinics. We've been reporting on this shadowy corner of the medical marketplace, in which clinics charge consumers thousands of dollars for untested, unscientific and unproven treatments.
FDA Commissioner Scott Gottlieb turned his gun sights squarely on the "bad actors" in this field when he announced his agency's regulatory initiative. Among them are clinics that charge desperate patients as much as $15,000, not including travel expenses, for treatments that are seldom covered by insurance. The treatments are not approved by the FDA and are backed by virtually no scientific evidence to prove their efficacy.
"The rapid growth and promise of this field has increasingly sowed the ground for the entry of some unscrupulous actors, who have opportunistically seized on the clinical potential of regenerative medicine to make deceptive claims to patients about unproven and, in some cases, dangerous products," Gottlieb said. "By exploiting the lack of consumer understanding of this area, as well as the fear and uncertainties posed by the diseases these bad actors claim to treat, they're jeopardizing the legitimacy and advancement of the entire field."
Some clinics have tried to skirt FDA regulations by claiming that by treating liposuctioned fat to extract stem cells, they're engaging in "minimal manipulation" of patients' own tissues, a well-known exemption to the agency's definition of a regulated drug.
The FDA final guidelines say "no dice" to that. Minimal manipulation, they state, means minor handling such as rinsing or filtration to remove debris and other impurities. Taking steps to "isolate stem cells," as many clinics claim they're doing, is out of bounds and requires special licensing and possible inspections.
Researchers Leigh Turner and Paul Knoepfler found 570 U.S. clinics marketing stem cell interventions, with "hot spots" (marked with blue stars) of high concentrations of clinics in Southern California, Phoenix, New York, San Antonio and Austin, Texas.
Researchers Leigh Turner and Paul Knoepfler found 570 U.S. clinics marketing stem cell interventions, with "hot spots" (marked with blue stars) of high concentrations of clinics in Southern California, Phoenix, New York, San Antonio and Austin, Texas. (Turner and Knoepfler, Cell/Stem Cell)
Using tissue-derived stem cells to treat conditions unrelated to the original tissue is also nonexempt, the FDA says. That's a shot at the claims of stem-cell clinics that they can use fat-derived stem cells to treat disorders that have nothing to do with fat, such as multiple sclerosis, Parkinson's, pulmonary conditions or rheumatoid arthritis — conditions that stem-cell clinics around the country imply they can treat.
The FDA's initiative this week adds specifics to a theme Gottlieb has been articulating since he took over the agency on May 11. In August, the FDA seized nearly 500 doses of a smallpox vaccine that was to be combined with stem cells derived from body fat and administered to patients in clinics in Beverly Hills and Rancho Mirage, Calif. The agency also published a blistering warning letter delivered to U.S. Stem Cell Clinic of Sunrise, Fla., for "marketing stem cell products without FDA approval."
U.S. Stem Cell ran a Florida clinic that reportedly injected a stem-cell solution into the eyeballs of three elderly women suffering macular degeneration. According to the New England Journal of Medicine, the patients suffered permanent partial or complete blindness because of the treatment. The firm's chief scientific officer, Kristin Comella, testified at an FDA hearing in 2016 that its stem-cell treatments should be exempted under the "minimally manipulated" standard. She said the number of "adverse events" that had been reported among thousands of patients was "just a handful." She gave her testimony before the vision cases were reported by the New England Journal.
U.S. Stem Cell has acknowledged performing the eye procedures, but says that it has ceased doing them and that it settled with the patients under conditions of confidentiality.
The FDA, for its part, has issued just a handful of warning letters to stem-cell clinics, including the notice to U.S. Stem Cell. It should be taking firmer action, Turner says. "If Thursday the FDA had put out a press release and said, 'We've issued warning letters to 20 businesses' and picked 20 of the more visible businesses in this marketplace, that would have had a meaningful effect."
Instead, he argues, the FDA is just deepening a hole that it created itself. "If the FDA had done something meaningful around 2009 and these businesses hadn't proliferated," he says, "there wouldn't be this huge regulatory challenge facing the FDA, where there are hundreds of these businesses and they say they can't possibly regulate them all, so they have to prioritize their resources and just pick the most outrageous ones.
"The FDA is part of the very problem they're now responsible for addressing. They did very little for years, and if they had done a better job of it over the last seven or eight years, we'd be in a very different place."
Keep up to date with Michael Hiltzik. Follow @hiltzikm on Twitter, see his Facebook page, or email michael.hiltzik@latimes.com.
We are headed to double digits
US Stem Cell Inc (OTCMKTS:USRM) Momentum Favorite Back on the Move
By Jermaine Farmer - March 9, 2018
US Stem Cell Inc (OTCMKTS:USRM) has been back in rally mode in recent action. This was a major momentum play from early last year – one of the most dramatic stories on the OTC from Jan to March of 2017, rising from deep sub-penny levels to nearly $0.20/share in that time. It was a truly extraordinary run. The catalyst then had to do with a lawsuit that was worked out in a benign fashion. However, this time around, the stock is up a quick 50% in a few days, and breaking out to new multi-month highs, and the move appears to be driven by some more basic ideas related to its core stem cell strategy.
To augment that narrative, the company just announced its participation in this year’s fourth annual Academy of Regenerative Practices’ Conference, which kicked off last week and ran through March 2 & 3 at the Bonaventure Resort & Spa in Weston, Florida. That conference has come and gone at this point, so the stock’s continued advance raises our eyebrows. We always get interested when a company has made a key presentation and then starts to run on no new headlines. It has the scent of possible “smart money” flows based on key ideas presented at the event. But first, before we get into that thesis, here is a quick overview of the company for those who aren’t familiar with the name.
US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
The company’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
According to company materials, “USRM is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society
As noted above, shares of USRM have been back on the move following the company’s appearance at the Academy of Regenerative Practices’ Conference earlier this month.
“It’s always such a pleasure to gather with this rapidly expanding community of scientific experts to connect and collaborate,” said Dr. Kristin Comella, USRM’s Chief Science Officer and President of the Academy of Regenerative Practices. “This is an incredible time for regenerative medicine, and connecting with my colleagues in the scientific community who are passionate about it is always such a treat. I look forward to another successful conference with my colleagues from around the world.”
The chart shows 40% piled on for shareholders of the company during the trailing month. This is emblematic of the stock. USRM is a stock with a past that has featured a litany of sudden rips to the upside. In addition, the company has registered increased average transaction volume recently, with the past month seeing 49% over the long run average.
Currently trading at a market capitalization of $18.7, USRM has a bankroll ($957K) of cash on the books, which must be weighed relative to about $3.2M in total current liabilities. USRM is pulling in trailing 12-month revenues of $5M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 106.4%. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $USRM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $USRM, either long or short, and we have not been compensated for this article.
Lets close this above .07 with 7+ million in volume
GREAT ARTICLE.. We are going higher
US Stem Cell Inc (OTCMKTS:USRM) Momentum Favorite Back on the Move
By Jermaine Farmer - March 9, 2018
SHARE Facebook Twitter
US Stem Cell Inc (OTCMKTS:USRM) has been back in rally mode in recent action. This was a major momentum play from early last year – one of the most dramatic stories on the OTC from Jan to March of 2017, rising from deep sub-penny levels to nearly $0.20/share in that time. It was a truly extraordinary run. The catalyst then had to do with a lawsuit that was worked out in a benign fashion. However, this time around, the stock is up a quick 50% in a few days, and breaking out to new multi-month highs, and the move appears to be driven by some more basic ideas related to its core stem cell strategy.
To augment that narrative, the company just announced its participation in this year’s fourth annual Academy of Regenerative Practices’ Conference, which kicked off last week and ran through March 2 & 3 at the Bonaventure Resort & Spa in Weston, Florida. That conference has come and gone at this point, so the stock’s continued advance raises our eyebrows. We always get interested when a company has made a key presentation and then starts to run on no new headlines. It has the scent of possible “smart money” flows based on key ideas presented at the event. But first, before we get into that thesis, here is a quick overview of the company for those who aren’t familiar with the name.
US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
The company’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
According to company materials, “USRM is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.”
As noted above, shares of USRM have been back on the move following the company’s appearance at the Academy of Regenerative Practices’ Conference earlier this month.
“It’s always such a pleasure to gather with this rapidly expanding community of scientific experts to connect and collaborate,” said Dr. Kristin Comella, USRM’s Chief Science Officer and President of the Academy of Regenerative Practices. “This is an incredible time for regenerative medicine, and connecting with my colleagues in the scientific community who are passionate about it is always such a treat. I look forward to another successful conference with my colleagues from around the world.”
The chart shows 40% piled on for shareholders of the company during the trailing month. This is emblematic of the stock. USRM is a stock with a past that has featured a litany of sudden rips to the upside. In addition, the company has registered increased average transaction volume recently, with the past month seeing 49% over the long run average.
Currently trading at a market capitalization of $18.7, USRM has a bankroll ($957K) of cash on the books, which must be weighed relative to about $3.2M in total current liabilities. USRM is pulling in trailing 12-month revenues of $5M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 106.4%. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $USRM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
https://oracledispatch.com/2018/03/09/us-stem-cell-inc-otcmktsusrm-momentum-favorite-back-move/
and close at the HOD..
Can we do 3 consecutive days with 6 million shares traded?
.0645 +0.003 (4.88%) Volume 5,053,244.. Looking STRONG.!!
11:34:47 - 1,249,900 @ .062 traded on the ask
Joe Rogan - MEL GIBSON STEM CELLS | "Why is it not legal in America?"
(CNN)Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the development of stem cell therapies proved to be safe and effective.
Dr. Scott Gottlieb, the FDA commissioner, and Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, co-authored a new paper detailing the delicate balance between safety and innovation when it comes to the possibilities of using stem cells in medicine.
"Our aim is to refashion our traditional tools for regulation to meet the challenges and opportunities presented by such highly innovative products as cell-based regenerative medicine," they wrote in the paper, published Thursday in the New England Journal of Medicine. Divisions run deep over how to regulate stem cell clinics.
Stem cells have the potential to develop into many cell types in the body. Some studies suggest that stem cells may help the nearly blind to see and could reverse signs of aging. Research has even explored using stem cells to create red blood cells to replenish blood shortages during emergencies.
"However, despite the increasingly widespread use of stem cells in techniques being labeled as regenerative medicine, clinical benefit has not been clearly shown in most instances," Gottlieb and Marks wrote.
The FDA hopes to change that, while continuing efforts to regulate the industry.
'A sweet spot of stem cell oversight'
"This more reflects an update from the FDA on where their thinking stands on stem cells. I don't see it as backing down from the hoped-for stepping up of FDA oversight of clinics," said Paul Knoepfler, professor of cell biology and human anatomy at the University of California, Davis School of Medicine, who wrote a blog post about the new paper.
"The FDA seems to be saying they want to find a sweet spot of stem cell oversight where they encourage innovation by good citizens and yet also carefully regulate this sphere as well as encouraging those interested in transplanting stem cells into patients to work with the FDA," he said.
Stem cell study offers hope for ALS
Knoepfler co-authored a paper, published in the journal Cell Stem Cell in 2016, that found unapproved stem cell interventions being marketed at 570 clinics across the US. "Hot spot" cities where there were clusters of clinics included Beverly Hills, California; New York; San Antonio; Los Angeles; Austin, Texas; Scottsdale, Arizona, and Phoenix.
Although Gottlieb and Marks didn't mention clinics in their paper, they noted that facilitating the availability of safe and effective therapies was part of the FDA's oversight of regenerative medicine products, including new stem cell therapies.
The FDA will provide tools to encourage individual or small groups of physicians to collaborate in support of the development of a stem cell or other regenerative medicine product, they wrote.
A milestone in stem cell research
A milestone in stem cell research
Gottlieb and Marks also said the FDA is encouraging investigators who are involved in such innovative product development to engage in dialogue with the agency early on in the research process.
"It feels like the FDA leadership is in essence telling them, 'Do the right thing, and we'll help you with a trial, even if you aren't a big university or company,' " Knoepfler said. "It's reassuring to see though that the FDA still emphasizes it is crucial to have data and follow the rules."
The FDA held a Grand Rounds webcast on Thursday detailing how its scientists are examining strategies and methods to predict the reliability of how certain cell-based therapies will perform in humans.
The ability to make such predictions could be a big step toward getting safe and effective FDA-approved treatments to patients in the future.
Predicting the future
For many investigational stem cell-based products, it remains unclear whether the measurements currently used to characterize products will predict their clinical effectiveness, according to the FDA.
As of now, stem cell-based products submitted to the FDA in clinical trial proposals are characterized using a small number of cell surface markers and simple measures of cell product activity -- but is that enough to truly predict clinical outcomes?
Stem Cells Fast Facts
Answering that question has become one of many focuses of the FDA's Multipotent Stromal Cell Consortium, a large team of scientists studying adult multipotent stromal cells. These are stem cells that can differentiate into a variety of cell types and could contribute to tissue repair or help replace, restore or regenerate other parts of the body.
Steven Bauer, chief of the cellular and tissues therapy branch in the Center for Biologics Evaluation and Research, gave the keynote presentation at Thursday's Grand Rounds and focused on how, when multipotent stromal cells are studied for use as therapies, predictability is key.
"We can use some of this information to help generate standards in this field," he said. "There is a tremendous amount of interest now in developing standards that will facilitate the development of regenerative medicine and products."
Follow CNN Health on Facebook and Twitter
See the latest news and share your comments with CNN Health on Facebook and Twitter.
All in all, "combined with the publication today of New England Journal of Medicine article, the FDA wants to assure that developers of regenerative medicine therapies understand the regulatory pathways that are available," the agency said in a written statement emailed to CNN by a FDA spokesperson.
"The FDA is committed to ensuring that patients have access to safe and effective regenerative medicine products as efficiently as possible. We are also committed to making sure we take action against products being unlawfully marketed that pose a potential significant risk to their safety," the statement said.
"The agency has adopted a risk-based and science-based approach that builds upon existing regulations to support innovative product development while clarifying the FDA's authorities and enforcement priorities. This risk-based approach allows product developers time to engage with the FDA, to determine if they need to submit a marketing authorization application and, if so, submit their application to the FDA for approval," the statement said.
(CNN)Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the development of stem cell therapies proved to be safe and effective.
Dr. Scott Gottlieb, the FDA commissioner, and Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, co-authored a new paper detailing the delicate balance between safety and innovation when it comes to the possibilities of using stem cells in medicine.
"Our aim is to refashion our traditional tools for regulation to meet the challenges and opportunities presented by such highly innovative products as cell-based regenerative medicine," they wrote in the paper, published Thursday in the New England Journal of Medicine. Divisions run deep over how to regulate stem cell clinics.
Stem cells have the potential to develop into many cell types in the body. Some studies suggest that stem cells may help the nearly blind to see and could reverse signs of aging. Research has even explored using stem cells to create red blood cells to replenish blood shortages during emergencies.
"However, despite the increasingly widespread use of stem cells in techniques being labeled as regenerative medicine, clinical benefit has not been clearly shown in most instances," Gottlieb and Marks wrote.
The FDA hopes to change that, while continuing efforts to regulate the industry.
'A sweet spot of stem cell oversight'
"This more reflects an update from the FDA on where their thinking stands on stem cells. I don't see it as backing down from the hoped-for stepping up of FDA oversight of clinics," said Paul Knoepfler, professor of cell biology and human anatomy at the University of California, Davis School of Medicine, who wrote a blog post about the new paper.
"The FDA seems to be saying they want to find a sweet spot of stem cell oversight where they encourage innovation by good citizens and yet also carefully regulate this sphere as well as encouraging those interested in transplanting stem cells into patients to work with the FDA," he said.
Stem cell study offers hope for ALS
Knoepfler co-authored a paper, published in the journal Cell Stem Cell in 2016, that found unapproved stem cell interventions being marketed at 570 clinics across the US. "Hot spot" cities where there were clusters of clinics included Beverly Hills, California; New York; San Antonio; Los Angeles; Austin, Texas; Scottsdale, Arizona, and Phoenix.
Although Gottlieb and Marks didn't mention clinics in their paper, they noted that facilitating the availability of safe and effective therapies was part of the FDA's oversight of regenerative medicine products, including new stem cell therapies.
The FDA will provide tools to encourage individual or small groups of physicians to collaborate in support of the development of a stem cell or other regenerative medicine product, they wrote.
A milestone in stem cell research
A milestone in stem cell research
Gottlieb and Marks also said the FDA is encouraging investigators who are involved in such innovative product development to engage in dialogue with the agency early on in the research process.
"It feels like the FDA leadership is in essence telling them, 'Do the right thing, and we'll help you with a trial, even if you aren't a big university or company,' " Knoepfler said. "It's reassuring to see though that the FDA still emphasizes it is crucial to have data and follow the rules."
The FDA held a Grand Rounds webcast on Thursday detailing how its scientists are examining strategies and methods to predict the reliability of how certain cell-based therapies will perform in humans.
The ability to make such predictions could be a big step toward getting safe and effective FDA-approved treatments to patients in the future.
Predicting the future
For many investigational stem cell-based products, it remains unclear whether the measurements currently used to characterize products will predict their clinical effectiveness, according to the FDA.
As of now, stem cell-based products submitted to the FDA in clinical trial proposals are characterized using a small number of cell surface markers and simple measures of cell product activity -- but is that enough to truly predict clinical outcomes?
Stem Cells Fast Facts
Answering that question has become one of many focuses of the FDA's Multipotent Stromal Cell Consortium, a large team of scientists studying adult multipotent stromal cells. These are stem cells that can differentiate into a variety of cell types and could contribute to tissue repair or help replace, restore or regenerate other parts of the body.
Steven Bauer, chief of the cellular and tissues therapy branch in the Center for Biologics Evaluation and Research, gave the keynote presentation at Thursday's Grand Rounds and focused on how, when multipotent stromal cells are studied for use as therapies, predictability is key.
"We can use some of this information to help generate standards in this field," he said. "There is a tremendous amount of interest now in developing standards that will facilitate the development of regenerative medicine and products."
Follow CNN Health on Facebook and Twitter
See the latest news and share your comments with CNN Health on Facebook and Twitter.
All in all, "combined with the publication today of New England Journal of Medicine article, the FDA wants to assure that developers of regenerative medicine therapies understand the regulatory pathways that are available," the agency said in a written statement emailed to CNN by a FDA spokesperson.
"The FDA is committed to ensuring that patients have access to safe and effective regenerative medicine products as efficiently as possible. We are also committed to making sure we take action against products being unlawfully marketed that pose a potential significant risk to their safety," the statement said.
"The agency has adopted a risk-based and science-based approach that builds upon existing regulations to support innovative product development while clarifying the FDA's authorities and enforcement priorities. This risk-based approach allows product developers time to engage with the FDA, to determine if they need to submit a marketing authorization application and, if so, submit their application to the FDA for approval," the statement said.
We are here, watching and waiting..
Can you please provide a link backing your statement.. ("the FDA just made it clearer, that "clinics" like USRM and Comella run are IN THE TARGET SITES for the FDA to fully go after for shut-down")
300 x .062 = $18.6 plus commission $6.95 = $25.25. I doubt this is someone actually buying or part of a filled limit order. Has to mean something. Yesterday was a lot of 100- 200- 300- & 500 share trades.. Hmm
New synthetic polymer kills antibiotic-resistant superbugs from the inside out
March 5th, 2018
Normal cells of the Acinetobacter baumannii bacteria after treatment with the synthetic polymers, showing that the...
Normal cells of the Acinetobacter baumannii bacteria after treatment with the synthetic polymers, showing that the cytoplasmic substances within the bacterial cell membrane have precipitated, killing the bacteria
VIEW GALLERY - 3 IMAGES
A research team composed of scientists from the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research has produced a new synthetic molecule that can target and kill five multidrug-resistant bacteria. This synthetic polymer was found to be non-toxic and could enable entirely new classes of therapeutics to address the growing problem of antibiotic-resistant superbugs.
The synthetic molecules are called guanidinium-functionalized polycarbonates and were found to be both biodegradable and non-toxic to human cells. Essentially, the positively-charged synthetic polymer enters a living body and binds specifically to certain bacteria cells by homing in on a microbial membrane's related negative charge. Once attached to the bacteria, the polymer crosses the cell membrane and triggers the solidification of proteins and DNA in the cell, killing the bacteria.
"We have demonstrated the first example of a biodegradable synthetic macromolecule with broad-spectrum antimicrobial activity in mice, unique killing mechanism and no toxicity," says Yi Yan Yang, one of the authors on the study. "Once the polymer finishes its job of killing the bacteria, it will be naturally degraded after three days and will not remain in the body. This antimicrobial agent shows great promise for the treatment and prevention of multidrug-resistant systemic infections."
The four-step killing mechanism of the polymer: (1) the positively-charged polymer binds to the bacteria cell...
In mouse experiments the molecules were successful in eradicating five commonly known superbugs found in hospitals around the world. The process showed no notable signs of toxicity in the mice and following multiple treatments the bacteria displayed no signs of developing a resistance to the polymers.
Researchers at IBM have been working for several years to develop synthetic polymers that have a variety of medical uses. Back in 2012, a research team stumbled across what they then called "ninja polymers." The revelation that these synthetic molecules could target and kill bacteria led to an exciting series of discoveries the team calls "macromolecular therapeutics."
"In 2016, we demonstrated the efficacy of synthetic polymers to combat deadly viral diseases," explains James Hedrick, from IBM Research. "The current research for treating bacterial infections rounds out our ability to someday treat a spectrum of infectious diseases with a single, new type of mechanism without the onset of resistance."
The next phase of the research is to work to develop the technology into a specific antimicrobial treatment that can be clinically tested in humans and hopefully become a new way to treat infections in the body.
https://newatlas.com/synthetic-molecule-polymer-treat-resistant-bacteria/53676/
Joe Rogan - MEL GIBSON STEM CELLS | "Why is it not legal in America?"
(CNN)Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the development of stem cell therapies proved to be safe and effective.
Dr. Scott Gottlieb, the FDA commissioner, and Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, co-authored a new paper detailing the delicate balance between safety and innovation when it comes to the possibilities of using stem cells in medicine.
"Our aim is to refashion our traditional tools for regulation to meet the challenges and opportunities presented by such highly innovative products as cell-based regenerative medicine," they wrote in the paper, published Thursday in the New England Journal of Medicine.
Divisions run deep over how to regulate stem cell clinics
Divisions run deep over how to regulate stem cell clinics
Stem cells have the potential to develop into many cell types in the body. Some studies suggest that stem cells may help the nearly blind to see and could reverse signs of aging. Research has even explored using stem cells to create red blood cells to replenish blood shortages during emergencies.
"However, despite the increasingly widespread use of stem cells in techniques being labeled as regenerative medicine, clinical benefit has not been clearly shown in most instances," Gottlieb and Marks wrote.
The FDA hopes to change that, while continuing efforts to regulate the industry.
'A sweet spot of stem cell oversight'
"This more reflects an update from the FDA on where their thinking stands on stem cells. I don't see it as backing down from the hoped-for stepping up of FDA oversight of clinics," said Paul Knoepfler, professor of cell biology and human anatomy at the University of California, Davis School of Medicine, who wrote a blog post about the new paper.
"The FDA seems to be saying they want to find a sweet spot of stem cell oversight where they encourage innovation by good citizens and yet also carefully regulate this sphere as well as encouraging those interested in transplanting stem cells into patients to work with the FDA," he said.
Stem cell study offers hope for ALS
Stem cell study offers hope for ALS 08:29
Knoepfler co-authored a paper, published in the journal Cell Stem Cell in 2016, that found unapproved stem cell interventions being marketed at 570 clinics across the US. "Hot spot" cities where there were clusters of clinics included Beverly Hills, California; New York; San Antonio; Los Angeles; Austin, Texas; Scottsdale, Arizona, and Phoenix.
Although Gottlieb and Marks didn't mention clinics in their paper, they noted that facilitating the availability of safe and effective therapies was part of the FDA's oversight of regenerative medicine products, including new stem cell therapies.
The FDA will provide tools to encourage individual or small groups of physicians to collaborate in support of the development of a stem cell or other regenerative medicine product, they wrote.
A milestone in stem cell research
A milestone in stem cell research 01:50
Gottlieb and Marks also said the FDA is encouraging investigators who are involved in such innovative product development to engage in dialogue with the agency early on in the research process.
"It feels like the FDA leadership is in essence telling them, 'Do the right thing, and we'll help you with a trial, even if you aren't a big university or company,' " Knoepfler said. "It's reassuring to see though that the FDA still emphasizes it is crucial to have data and follow the rules."
The FDA held a Grand Rounds webcast on Thursday detailing how its scientists are examining strategies and methods to predict the reliability of how certain cell-based therapies will perform in humans.
The ability to make such predictions could be a big step toward getting safe and effective FDA-approved treatments to patients in the future.
Predicting the future
For many investigational stem cell-based products, it remains unclear whether the measurements currently used to characterize products will predict their clinical effectiveness, according to the FDA.
As of now, stem cell-based products submitted to the FDA in clinical trial proposals are characterized using a small number of cell surface markers and simple measures of cell product activity -- but is that enough to truly predict clinical outcomes?
Stem Cells Fast Facts
Stem Cells Fast Facts
Answering that question has become one of many focuses of the FDA's Multipotent Stromal Cell Consortium, a large team of scientists studying adult multipotent stromal cells. These are stem cells that can differentiate into a variety of cell types and could contribute to tissue repair or help replace, restore or regenerate other parts of the body.
Steven Bauer, chief of the cellular and tissues therapy branch in the Center for Biologics Evaluation and Research, gave the keynote presentation at Thursday's Grand Rounds and focused on how, when multipotent stromal cells are studied for use as therapies, predictability is key.
"We can use some of this information to help generate standards in this field," he said. "There is a tremendous amount of interest now in developing standards that will facilitate the development of regenerative medicine and products."
Follow CNN Health on Facebook and Twitter
See the latest news and share your comments with CNN Health on Facebook and Twitter.
All in all, "combined with the publication today of New England Journal of Medicine article, the FDA wants to assure that developers of regenerative medicine therapies understand the regulatory pathways that are available," the agency said in a written statement emailed to CNN by a FDA spokesperson.
"The FDA is committed to ensuring that patients have access to safe and effective regenerative medicine products as efficiently as possible. We are also committed to making sure we take action against products being unlawfully marketed that pose a potential significant risk to their safety," the statement said.
"The agency has adopted a risk-based and science-based approach that builds upon existing regulations to support innovative product development while clarifying the FDA's authorities and enforcement priorities. This risk-based approach allows product developers time to engage with the FDA, to determine if they need to submit a marketing authorization application and, if so, submit their application to the FDA for approval," the statement said.
We had 2 consecutive days of 6 million shares traded. If I saw 30-40-50 million shares traded, I might agree with you.
They fought hard to bring this down under .06, but they came up short. Good volume at 6.6 million, closed at .0615, and never went below yesterday's closing price. All positive signs. Go USRM..
Sudden large price movements can create false buy or sell signals in the RSI. It is, therefore, best used with refinements to its application or in conjunction with other, confirming technical indicators.
Some traders, in an attempt to avoid false signals from the RSI, use more extreme RSI values as buy or sell signals, such as RSI readings above 80 to indicate overbought conditions and RSI readings below 20 to indicate oversold conditions.
The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading.
Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not. An example of bearish divergence can unfold as follows: A security rises in price to $48 and the RSI makes a high reading of 65. After retracing slightly downward, the security subsequently makes a new high of $50, but the RSI only rises to 60. The RSI has bearishly diverged from the movement of price.
Read more: Relative Strength Index (RSI) https://www.investopedia.com/terms/r/rsi.asp#ixzz59BmdXza9
On TD Ameritrade, Trade Architect.. Go to charts, then click on studies, a drop box will appear, click RSI and it will be added.. Hope that helps..
RSI 14 @ 81.52
Reading Market-Maker Signals
The signs they send each other to move stock prices.
Many traders believe that market makers will "signal" moves in advance buy using small amounts of buys or sells as "signals". The "signals" are from one market maker to another.
## 100 I need shares.
## 200 I need shares badly, but do not take the stock down.
## 300 Take (or I am taking) the price down so I can load shares
## 400 Keep trading it sideways.
## 500 Gap the stock.
This is a theory put forth by a lot of penny stock and non-penny stock traders. This is not a guaranteed trading method but can lend some insight to comarket makerunications. It can pay to watch a few market makers of your favorite stock over several days or weeks to see if they follow these or other similar signals. That way, you can divine what they are going to do and jump in ahead of any move that may come.
FRIDAY! Another Double!
EGAN
Profiled @ $3.15 On Oct. 31st
Hit $8.00 FRIDAY
150+% Gain In A Few Weeks!
FalconStocks.com
100% Unbiased
Personally, I have worked on the Nasdaq Market Maker desk of a major firm and while the folks I worked with did not use any signs like the ones above, they did know what certain other MMs were about to do by watching them move their bids and asks. One example - When I first started and was sitting with one of the MMs, he said "See that? He dropped his ask and shows 1000 shares. He's a buyer." Say what? -- It wasn't even a minute later that the bids dropped lower after his 1000 share ask. As soon as the bids all dropped away, the asks from other MMs and internet brokers all fell below his. He then bought thousands of shares about $0.25 lower than where the bid was before his fake ask - on a $7 stock. These things happened ALL of the time. That market-maker then gave the shares to a broker for his client that placed the order $0.25 higher than he just paid, keeping the difference for himself.
Why signals? Why not just message or email?
One simple reason... calling/emailing one or more of the other market makers and telling them to "take the price down" or "I am going to gap the stock" would be 100% ILLEGAL. Collusion at it's finest. If caught, handcuffs could replace their Rolex for a trip downtown.
We've worked on OTC/Agency (Nasdaq and OTC-BB) desks and worked with many actual market makers. We can attest that many market makers will use certain signals. Some will use fake bids/offers to trick individual investors and day traders. They are still responsible for those bids/offers and would have to buy or sell there if their bid or offer is hit, but they post those to make others think they have an order and do not really want to buy or sell there.
This is all I found on what the 100 share trades could mean..
What is it with these 100 share trades.